Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NBE THERAPEUTICS
- Publication Date
- 2021-05-14
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] field of invention
[0002] The present invention relates to binding protein-toxin conjugates comprising one or more anthracycline toxoid moieties, and their use in immuno-oncology applications. Background technique
[0003] Binding protein-toxin conjugates, with antibody-drug conjugates (ADCs) as their most prominent representatives, have a great impact on cancer therapy, providing new therapeutic approaches for hitherto untreatable tumor types.
[0004] On the other hand, the discovery of immune checkpoints and the development of immune checkpoint inhibitors make the role of the immune system in cancer treatment and methods of stimulating the immune system or overcoming immune checkpoints (which individual tumors use for self-protection against immune system attacks) In focus again.
[0005] Although these two approaches are hotly discussed and represent major advances in cancer treatment, it is also clear that there are tumor types that cannot be treated with these ...